Xilio Therapeutics, Inc. (XLO)
Nasdaq · Pharmaceutical Preparations · Inc. DE
What they're doing
Between 2026-06-07 and 2026-09-05, public records show 1 signal for Xilio Therapeutics, Inc.. Most notable: 2026-06-12: Filed 8-K disclosing director or officer change. Federal contract obligations over the last 24 months total $0. This summary was assembled automatically from SEC EDGAR, USAspending.gov, U.S. Senate lobbying disclosures and Wikimedia pageview counts.
Generated 2026-09-05 from public records.
Signals, last 12 months
- Material 8-K filingFiled 8-K disclosing director or officer change
- Material 8-K filingFiled 8-K disclosing director or officer change
- Material 8-K filingFiled 8-K disclosing material agreement
- Material 8-K filingFiled 8-K disclosing director or officer change
- Material 8-K filingFiled 8-K disclosing director or officer change
Insider transactions
| Date | Insider | Role | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-03-26 | Shannon James Samuel | director | P | 5,000 | 8.79 | $43,950 |
| 2026-01-02 | Brennan Kevin M. | officer | S | 1,826 | 0.64 | $1,169 |
| 2026-01-02 | Frankenfield Christopher James | officer | S | 7,030 | 0.64 | $4,499 |
| 2026-01-01 | Luptakova Katarina | officer | M | 16,625 | — | — |
| 2026-01-01 | Brennan Kevin M. | officer | M | 5,000 | — | — |
| 2026-01-01 | Frankenfield Christopher James | officer | M | 19,375 | — | — |
| 2026-01-01 | Russo Rene | director | M | 44,250 | — | — |
| 2025-06-17 | Shannon James Samuel | director | P | 25,000 | 0.69 | $17,250 |
| 2025-06-16 | Shannon James Samuel | director | P | 45,000 | 0.69 | $31,050 |
| 2025-06-16 | Russo Rene | director | P | 36,289 | 0.68 | $24,677 |
| 2025-01-02 | Brennan Kevin M. | officer | S | 1,803 | 0.98 | $1,767 |
| 2025-01-02 | Frankenfield Christopher James | officer | S | 6,954 | 0.98 | $6,815 |
| 2025-01-01 | Brennan Kevin M. | officer | M | 5,000 | — | — |
| 2025-01-01 | Russo Rene | director | M | 44,250 | — | — |
| 2025-01-01 | Luptakova Katarina | officer | M | 16,625 | — | — |
| 2025-01-01 | Frankenfield Christopher James | officer | M | 19,375 | — | — |
| 2024-12-18 | GILEAD SCIENCES, INC. | ten percent owner | P | 1,759,978 | 1.04 | $1,830,377 |
Federal contracts
No federal contract actions on record for this recipient mapping.
Lobbying
No federal lobbying filings on record for this client mapping.
Public attention
No Wikipedia pageview data linked to this company.
Recent filings
- 2026-08-14 SCHEDULE 13G/A
- 2026-08-12 S-8
- 2026-08-12 10-Q
- 2026-08-12 8-K
- 2026-06-12 4
- 2026-06-12 4
- 2026-06-12 4
- 2026-06-12 4
- 2026-06-12 4
- 2026-06-12 4
- 2026-06-12 4
- 2026-06-12 8-K
- 2026-05-29 EFFECT
- 2026-05-27 CORRESP
- 2026-05-27 S-3/A
- 2026-05-18 UPLOAD
- 2026-05-15 SCHEDULE 13G
- 2026-05-15 SCHEDULE 13G/A
- 2026-05-15 SCHEDULE 13G/A
- 2026-05-15 SCHEDULE 13G